Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors

Abstract

Purpose Histone deacetylase inhibitors (HDIs) are promising anticancer therapies; however, drug resistance limits their efficacy. Here, we investigated the molecular mechanisms underlying HDI resistance, focusing on the mechanism of HDI-mediated induction of insulin-like growth factor 2 (IGF2) based on our previous study. Experimental design The methylation status of CCCTC binding factor (CTCF)-binding sites in the IGF2/H19 imprinting control region (ICR) were determined by methylation-specific PCR and bisulfite sequencing. The effectiveness of single or combinatorial blockade of DNA methyltransferase 1 (DNMT1) and histone deacetylase (HDAC) was evaluated using cell viability assay and patient-derived tumor xenograft (PDX) model. Results HDAC inhibition by vorinostat increased acetylated STAT3 (K685), resulting in transcriptional upregulation of DNMT1. DNMT1-mediated hypermethylation of CTCF-binding sites in the IGF2/H19 ICR decreased CTCF insulator activity, leading to a transcriptional upregulation of IGF2 and activation of the insulin-like growth factor 1 receptor (IGF-1R) pathway in cells with acquired or de novo vorinostat resistance. Strategies targeting DNMT1 or STAT3 diminished the IGF2 expression and potentiated vorinostat sensitivity in preclinical models of lung cancer with hypermethylation in the H19/IGF2 ICR. The degree of ICR hypermethylation correlated with vorinostat resistance in patient-derived lung tumors and in patients with hematological malignancies. Conclusions DNMT1-mediated transcriptional upregulation of IGF2 is a novel mechanism of resistance to HDIs, highlighting the role of epigenetic deregulation of IGF2 in HDI resistance and the potential value of the H19/IGF2 ICR hypermethylation and DNMT1 expression as predictive biomarkers in HDI-based anticancer therapies.

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma

“…DNMT3a and DNMT3b have mostly de novo DNA methylation activity, whereas DNMT1 plays a central role in preserving the patterns of DNA methylation through cell division ( 27 ). DNMT1 and DNA methylation is often considered as a key epigenetic regulatory mechanism and potential target for resistance to drugs ( 28 ).…”

Do social insects support Haig's kin theory for the evolution of genomic imprinting?

“…The allele-specific level of methylation of the imprinting control region (ICR) in this locus mediates the binding of CCCTC-binding factor (CTCF) that in turn controls the expression of H19 (maternal allele) or IGF2 (paternal allele). 69 The binding of CTCF is a pausing signal for RNA polymerase II (Pol II). DNA methylation inhibits CTCF binding, therefore enabling Pol II elongation resulting in skipping of an exon ( Fig.…”

H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition

“…This supports the conclusion that H19 is actively linked with cell aggressiveness and positively effects the progression of endometrial cancer. Several lines of evidence have been presented for the reasons why H19 is dysregulated in adult cancer tissues (15,16,31,32). H19 is responsive to the induction of pro-tumor factors in the cancer microenvironment including transforming growth factor-β and hypoxia (16).…”